Nirav Shah to Neoplasm Recurrence, Local
This is a "connection" page, showing publications Nirav Shah has written about Neoplasm Recurrence, Local.
Connection Strength
0.509
-
Pirtobrutinib in Covalent Bruton Tyrosine Kinase Inhibitor Pretreated Mantle-Cell Lymphoma. J Clin Oncol. 2023 08 20; 41(24):3988-3997.
Score: 0.127
-
Long-term outcomes and predictors of early response, late relapse, and survival for patients treated with bispecific LV20.19 CAR T-cells. Am J Hematol. 2022 12; 97(12):1580-1588.
Score: 0.121
-
Is autologous transplant in relapsed DLBCL patients achieving only a PET+ PR appropriate in the CAR T-cell era? Blood. 2021 03 11; 137(10):1416-1423.
Score: 0.109
-
Efficacy of Multiple SARS-CoV-2 Vaccine Doses in Patients with B Cell Hematologic Malignancies Receiving Chimeric Antigen Receptor T Cell Therapy: A Contemporary Cohort Analysis. Transplant Cell Ther. 2024 03; 30(3):285-297.
Score: 0.033
-
Immunoglobulin High Throughput Sequencing (Ig-HTS) Minimal Residual Disease (MRD) Analysis is an Effective Surveillance Tool in Patients With Mantle Cell Lymphoma. Clin Lymphoma Myeloma Leuk. 2024 04; 24(4):254-259.
Score: 0.033
-
BRUIN MCL-321: phase III study of pirtobrutinib versus investigator choice of BTK?inhibitor in BTK?inhibitor?naive mantle cell lymphoma. Future Oncol. 2022 Nov; 18(36):3961-3969.
Score: 0.031
-
Impact of Chronic Kidney Disease and Acute Kidney Injury on Safety and Outcomes of CAR T-Cell Therapy in Lymphoma Patients. Clin Lymphoma Myeloma Leuk. 2022 11; 22(11):863-868.
Score: 0.030
-
Trends in postrelapse survival in classic Hodgkin lymphoma patients after experiencing therapy failure following auto-HCT. Blood Adv. 2020 01 14; 4(1):47-54.
Score: 0.025